Elsevier

European Geriatric Medicine

Volume 4, Issue 4, September 2013, Pages 221-225
European Geriatric Medicine

Research paper
Hepcidin in anaemic geriatric patients with non-dialysis chronic kidney disease (ND-CKD)

https://doi.org/10.1016/j.eurger.2013.04.010Get rights and content

Abstract

Purpose

Although data respecting prevalence of anemia in elderly non-dialysis chronic kidney disease (ND-CKD) patients are still rare, prevalence is supposed to be high, as CKD and anemia increase with age. Hepcidin is a key regulator of iron homeostasis and elevated serum levels reduce enteral iron resorption, making oral iron substitution ineffective. In this setting, a state of functional iron deficiency may develop in ND-CKD and lead to anaemia due to iron-restricted erythropoiesis. Dependence of hepcidin on glomerular filtration rate (GFR) in younger ND-CKD patients could be shown recently. The present study was intended to analyse the dependence of serum hepcidin levels on GFR in anaemic geriatric patients > 60 years suffering from ND-CKD.

Methods

Explorative study; 53 patients were selected among in-patients of geriatric department; selection criteria were: non-dialysis CKD, presence of anemia (< 12 g/dL in women, < 13 g/dL in men); transferrin saturation (TSAT) < 16%, C-reactive protein (CRP) < 5 mg/L. Serum hepcidin was analysed by a commercially available ELISA kit (DRG, Marburg, Germany). Findings were evaluated by statistical means.

Results

Data reveal a positive correlation between hepcidin and ferritin (P < 0.001) as well as between TSAT and GFR (P = 0.027) and a negative correlation between hepcidin and GFR (P = 0.035). These findings are of statistical significance at a significance level of 0.05. All analyses are of an explorative nature.

Conclusions

As seen in younger patients, we could show a similar dependence of hepcidin serum levels on GFR in elderly anaemic patients suffering from ND-CKD. This finding underlines the option for intravenous iron supplementation in ND-CKD of the elderly. Randomized studies are needed.

Introduction

Anemia is highly prevalent in the elderly [1] and particularly in chronic kidney disease (CKD) with a stage dependent prevalence rate of more than 40% to > 70% [2], [3], [4]. Although data respecting prevalence of anemia in elderly non-dialysis chronic kidney disease (ND-CKD), patients are still rare, prevalence is supposed to be high, as CKD and anemia increase with age [1], [5]. Anemia is an acknowledged risk factor in pre-dialysis ND-CKD patients for morbidity with increased risk of cerebrovascular [6] and cardiovascular [7], [8], [9] events as well as the progression of CKD [10], [11].

Although pathogenesis of anemia in CKD is multifactorial involving inadequate erythropoietin production and iron-restricted erythropoiesis [12], a large number of CKD patients suffer from insufficient iron stores: analysis of CKD patients in the setting of the Third National Health and Nutrition Examination Survey (NHANES III) revealed that more than 40% of the patients with a glomerular filtration rate (GFR) < 60 mL/min did not have sufficient iron stores [13] to support erythropoiesis as judged by the National Kidney Foundation guidelines [14].

Hepcidin is a key regulator of iron homeostasis [15]: high concentrations of hepcidin inhibit intestinal iron absorption and iron release from macrophages and hepatocytes [16]. As the protein is renally released, it is likely to play a role in renal anemia, possibly causing a state of functional iron deficiency (i.e. iron deficiency with full iron stores) due to elevated serum hepcidin levels and consequently, an iron-restricted erythropoiesis. Treatment of iron deficiency in ND-CKD would avoid cost-intensive application of erythropoiesis stimulating agents (ESA) or reduce their dosage [17]. Although recent data shows that intravenous iron substitution is likely to be more effective than oral iron substitution in anaemic ND-CKD patients [18], it is no standard practice yet in these patients [19]. Considering the hepcidin mechanism, oral substitution remains challenging for this patient group due to limited enteral absorption and gastrointestinal side effects. Intravenous iron substitution offers an alternative, although side effects, like anaphylactic reactions can be associated. The improvement of therapeutic strategies in geriatric ND-CKD patients demands better understanding of the role of hepcidin in pathophysiology of ND-CKD. Recently, dependence of hepcidin serum levels on GFR has been shown in anaemic younger ND-CKD patients [20]. Our explorative study was therefore intended to analyse serum hepcidin levels in connection with haematological parameters and GFR in anaemic ND-CKD patients > 60 years.

Section snippets

Material and methods

The study is of an explorative nature. Between February and June 2011, a number of 221 geriatric in-patients at our university hospital were consecutively screened. Among these patients, only 53 met with inclusion criteria: 22 (41.5%) men and 31 (58.5%) women. This patient cohort consisted of 42 patients with ND-CKD and 11 controls without ND-CKD. Selection criteria for patients according to groups 1–3 and 5 (Table 1) were:

  • non-dialysis CKD;

  • presence of anemia;

  • TSAT < 16% (group 5: TSAT normal);

Descriptive analysis

Anemia was found in all patients (group 1–3 and 5), except in control persons. TSAT was low in all patients of group 1–3 and normal in patients of group 5 as well as in all control persons. A slight cobalamin deficiency (180 pg/mL to 1100 pg/mL) with 169 pg/mL was found in one patient of group 2, but as neither megaloblastic anemia nor pancytopenia were present, no association of anemia with cobalamin deficiency was assumed. The patient therefore remained in group 2. Ferritin was low (< 30 μg/L) in

Discussion

Anemia is a frequent problem in elderly ND-CKD patients and association with functional iron deficiency is supposed. The role of hepcidin in connection with anemia in elderly ND-CKD patients is still unclear. A recent study of younger ND-CKD patients showed a dependence of serum hepcidin levels on GFR [20]: Zaritsky et al. managed to show an increase of serum hepcidin levels in association with a decrease of GFR in dependence of the KDOQI stage of ND-CKD patients < 40 years and they assumed a

Disclosure of interest

G. Röhrig and RJ. Schulz have received fees by Vifor Pharma for oral speech contributions at congress. V. Weiß and C. Nobbe state that there are no conflicts of interest.

Acknowledgements

The authors want to thank the German Geriatric Society (DGG) and the German Hemato-Oncologic Society (DGHO) for awarding this study the “Award of Scientific Advancement 2010” in Potsdam, Germany.

They further want to thank Dr. Alfred Janetzko for scientific support in Hepcidin ELISA analysis.

References (29)

  • L. De Nicola et al.

    Prevalence and prognosis of mild anemia in non-dialysis chronic kidney disease: a prospective cohort study in outpatient renal clinics

    Am J Nephrol

    (2010)
  • D. Munikrishnappa

    Chronic kidney disease (CKD) in the elderly – a geriatrician's perspective

    Aging Male

    (2007)
  • M.L. Thorp et al.

    Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease

    Nephrology (Carlton)

    (2009)
  • G.F. Strippoli et al.

    Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials

    J Am Soc Nephrol

    (2004)
  • Cited by (0)

    View full text